Tilray stock soared 14% today as investors rushed to position themselves ahead of President Trump’s historic executive order reclassifying marijuana from Schedule I to Schedule III. The move marks a watershed moment for cannabis companies that have struggled for years under strict federal regulations. What happens next could transform the entire industry.
🔥 Quick Facts
- TLRY jumped 14% to $14.44 on December 18, 2025 ahead of Trump’s announcement
- Trump signed the executive order reclassifying marijuana to Schedule III from Schedule I
- Schedule III status places marijuana alongside ketamine and some anabolic steroids with lower abuse potential
- Cannabis businesses could now deduct federal tax expenses and access FDA medical research opportunities
The Historic Executive Order That Changed Everything
Intuit emerges as best software stock for 2026 while stock crashes to bargain levels analysts didn’t expect
2026 tax brackets shock Americans with hidden paycheck truth nobody expected
President Trump signed the executive order on December 18, 2025, at 1:30 p.m. Eastern Time, directing federal agencies to reclassify marijuana immediately. This action removes cannabis from the Schedule I category alongside heroin and ecstasy. The reclassification opens pathways the industry has pursued for years.
The order doesn’t legalize marijuana but fundamentally changes how the government treats it. Federal agencies now have authority to conduct medical research and pharmaceutical development on cannabis. Most importantly, businesses can deduct ordinary business expenses on their federal tax returns.
Cannabis Stocks Rally Across the Board
Marcus Lemonis takes CEO role at Bed Bath & Beyond with $25M cost-cutting plan and watch what industry experts are saying about his next move
SPX surges 34 points at open with shocking tech recovery, here’s what caused the unexpected Venezuela rally
Beyond Tilray’s 14% surge, the broader cannabis market exploded with enthusiasm. Canopy Growth gained 21% to $2.33, while the AdvisorShares Pure US Cannabis ETF (MSOS) rose 5.5% to $7.05. Trading volume reached unprecedented levels across the sector.
This represents a stunning turnaround for an industry that has endured years of regulatory uncertainty. The cannabis ETF declined over 85% from its all-time high of $55.05 on February 10, 2021, reflecting investor disappointment when federal legalization didn’t materialize under prior administrations.
Financial Benefits and Tax Advantages Unlock Growth
| Benefit Category | Impact on Cannabis Businesses |
| Federal Tax Deductions | Companies can now claim ordinary business expense deductions previously denied |
| Medical Research Access | FDA gains authority to study cannabis for therapeutic applications and drug development |
| Regional Flexibility | Could enable interstate commerce and banking relationships for cannabis businesses |
| Insurance and Loans | Financial institutions may expand services to Schedule III cannabis operators |
Schedule III status provides tangible economic advantages that could reshape margins across leading cannabis cultivators and retailers. Tilray and competitors stand to reduce effective tax burdens substantially.
Why Wall Street Suddenly Believes in Cannabis Again
Industry veterans waited years for this moment. Since 2021, expectations for federal legalization repeatedly disappointed investors. Biden administration officials promised rescheduling but the process stalled in bureaucracy. Trump’s executive order bypasses lengthy regulatory procedures.
Investors recognize the practical benefits immediately. Tax deductions directly increase profitability. Medical research legitimacy attracts pharmaceutical partnerships. Banking access improves cash flow management. These concrete improvements justify today’s rally and suggest sustained momentum ahead.
What Happens to Tilray Stock Now That Schedule III Reclassification Is Official?
Tilray faces two potential paths forward. Sustainably higher valuations depend on execution—converting tax advantages into earnings growth and securing banking partnerships. The stock rallied on hope today but must deliver tangible financial improvements.
Regulatory uncertainty still exists. Federal implementation timelines remain unclear. States maintain separate cannabis laws. International operations face their own jurisdictional complexities. Success requires management navigating these nuances effectively while Scale opportunities emerge.
The Path Forward
Analysts project Tilray could reach $16-$25 per share if the company capitalizes on new tax advantages and research access. Conservative estimates suggest $8.50 as downside risk. The wide range reflects genuine uncertainty about execution and competitive dynamics in an increasingly mainstream cannabis market.
“One of the best things that could happen to Tilray right now is if the U.S. legalizes cannabis at the federal level. That would open up a significant opportunity, allowing pot growers to access banking services in the country more easily and ship cannabis across state lines.”
— The Motley Fool, Financial Analysis Commentary
Sources
- Barron’s – Coverage of Tilray stock surge and Trump executive order announcement
- CNBC – Trump marijuana reclassification to Schedule III details and implications
- The New York Times – Executive order text and federal policy changes
Patrick Graham is a business and finance journalist translating Wall Street’s complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world’s biggest moves.